Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

Michal Masar, Prokop Vodicka, Samuel Hricko, Andrea Janikova, Katerina Benesova, David Salek, Jana Salkova, Martina Filipova, Jan Galko, Vit Campr, Magdalena Klanova, Marek Trneny

Blood (2024) 144 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2024-208592

Published: 2024

Journal Articles

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Magdalena Klanova, Samuel Hricko, Michal Masar, David Salek, Prokop Vodicka, Natasa Kopalova, Petra Blahovcova, Katerina Benesova, Jozef Michalka, Jan Koren, Andrea Janikova, Marek Trneny

Blood (2023) 142 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2023-178208

Published: 2023

Journal Articles

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada

Blood (2023) 142 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2023-180155

Published: 2023

Journal Articles

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Aleš Obr, Pavel Klener, Jr., Andrea Janíková, Heidi Mocikova, David Belada, David Šálek, Alice Sýkorová, Andrea Jirkuvová, Tomáš Papajík, Marek Trněný

Blood (2021) 138 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2021-146589

Published: 2021

Journal Articles

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Aleš Obr, MD, Vit Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD PhD prof., Pavel Klener, Jr., MD PhD Assoc Prof, Andrea Janikova, MD PhD Assoc Prof, David Salek, MD PhD, David Belada, MD PhD, Robert Pytlik, Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Martin Simkovic, MD PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 1498.

https://doi.org/10.1182/blood.V130.Suppl_1.1498.1498

Published: 2017

Journal Articles

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Vit K Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD prof., Andrea Janikova, MD PhD, Assoc Prof, David Belada, Tomas Kozak, MD, PhD, Prof., David Salek, MD PhD, Alice Sykorova, MD PhD, Heidi Mocikova, MD, PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trneny

Blood (2016) 128 (22): 1779.

https://doi.org/10.1182/blood.V128.22.1779.1779

Published: 2016

Journal Articles

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Marek Trneny, MD, Pavel Klener, MD, David Belada, MD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, Samuel Vokurka, MD PhD, Jan Pirnos, MD, Katerina Kubackova, MD, Juraj Duras, MD, Jana Salkova, MD, David Salek, MD, Robert Pytlik, MD, PhD, Lucie Barsova, MD, Petr Kessler, MD, Ludmila Boudova, MD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jitka Dlouha, Katerina Benesova, MD

Blood (2014) 124 (21): 4425.

https://doi.org/10.1182/blood.V124.21.4425.4425

Published: 2014

Journal Articles

Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results

Pavel Klener, MD, PhD, Eva Fronkova, MD, PhD, Robert Pytlik, MD, PhD, Marketa Kalinova, D.Sc., PhD, Kristina Forsterova, D.Sc., PhD, David Belada, MD, Martin Simkovic, MD, David Salek, MD, PhD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, PhD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jozef Kubinyi, MD, PhD, Jiri Dolezal, MD, PhD, Ass.Prof., Jan Trka, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof.

Blood (2014) 124 (21): 1720.

https://doi.org/10.1182/blood.V124.21.1720.1720

Published: 2014

Journal Articles

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Vit Prochazka, M.D., Ph.D., Marek Trneny, MD, Ph.D., Prof., Andrea Janikova, MD, PhD, David Belada, M.D., Ph.D., Tomas Kozak, M.D., Ph.D., ass. prof., Tomas Papajik, MD, PhD, ass. prof., Vit Campr, MD, Ph.D., David Salek, MD, Ph.D., Robert Pytlik, MD, Ph.D., Alice Sykorova, MD, PhD, Milada Jankovska, MD, Jitka Dlouha

Blood (2013) 122 (21): 4354.

https://doi.org/10.1182/blood.V122.21.4354.4354

Published: 2013

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

Journal Articles

The Mystery of FDG-PET Avidity In Follicular Lymphoma. Does Microenvironment Play the Key Role?

Andrea Janikova, MD, PhD, Boris Tichy, Dr, Jana Supikova, Dr, Pavel Fabian, MD, PhD, Leos Kren, MD, PhD, Karol Bolcak, MD, David Salek, MD, Jozef Michalka, MD, Sarka Pospisilova, Dr, PhD, Jiri Mayer, MD, PhD

Blood (2010) 116 (21): 4138.

https://doi.org/10.1182/blood.V116.21.4138.4138

Published: 2010

Journal Articles

Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project

Blood (2010) 116 (21): 2882.

https://doi.org/10.1182/blood.V116.21.2882.2882

Published: 2010

Journal Articles

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

David Salek, MD, Ingrid Vasova, MD, Robert Pytlik, MD, David Belada, MD, PhD, Tomas Papajik, MD, PhD, Katerina Kubackova, MD, Jan Pirnos, MD, Ludmila Boudova, MD, PhD, Roman Kodet, MD, Petra Obrtlikova, MD, Hana Krejcova, Marek Trneny, MD, PhD

Blood (2008) 112 (11): 3745.

https://doi.org/10.1182/blood.V112.11.3745.3745

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

The Outcome of Diffuse Large B-Cell Lymphoma Patients with Testicular Involvement - Real World Data

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

The Mystery of FDG-PET Avidity In Follicular Lymphoma. Does Microenvironment Play the Key Role?

Median Absolute Lymphocyte Count Independently Predicts Survival of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-Chemotherapy: Analysis of 651 Patients Included In the Czech Lymphoma Project

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only